Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746229 | 0.85 | MEN1 (0.43) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL11567490 | 0.83 | SMN1; SMN2 (0.47) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL7151009 | 0.83 | AOC3 (0.49) | KMT2AMEN1KDM4EL3MBTL1CYP1A2 | |
| SCHEMBL29957820 | 0.82 | ALDH1A1 (0.54) | KDM4EL3MBTL1CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL249539 | 0.82 | ALDH1A1 (0.54) | KDM4EL3MBTL1CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL7333236 | 0.82 | CA12 (0.54) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL30681592 | 0.81 | ALDH1A1 (0.52) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL3460333 | 0.81 | ALDH1A1 (0.52) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL8119377 | 0.81 | ALDH1A1 (0.46) | CA12CA1CA2CA14KMT2A | |
| SCHEMBL464374 | 0.80 | CA12 (0.54) | CA12CA1CA2CA14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357565-A2 | New process for the synthesis of the levodopa | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1990-03-07 | — | — | EP | claimed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-3880667-A1 | METHOD OF FORMING MONOMERS AND FURFURAL FROM LIGNOCELLULOSE | Kat2Biz AB (SE) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127328-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020101563-A1 | METHOD OF FORMING MONOMERS AND FURFURAL FROM LIGNOCELLULOSE | KAT2BIZ AB (SE) | 2020-05-22 | — | — | WO | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232094-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018039442-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6306876-B1 | DRUGS WITH DIASTERIOMERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
| EP-0389876-A1 | New process for the synthesis of the N-methyl-3,4-dimethoxyphenylethylamine | Alfa Chemicals Italiana S.r.l. (IT) | 1990-10-03 | — | — | EP | disclosed |
| EP-0351382-A2 | Process for the synthesis of optically active aminoacids | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1990-01-17 | — | — | EP | disclosed |
| US-4622335-A | AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | CA12 4264/4885CA1 4162/4885CA2 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.